Uğur Şahin, BioNTech CEO (Andreas Arnold/picture-alliance/dpa/AP Images)
BioNTech nabs up to $90M for mpox vaccine as it begins PhI/II trial behind Moderna's lead
Building on its infectious disease work in Covid-19, malaria and tuberculosis, BioNTech is now rolling out a Phase I/II test of a jab to protect …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
